All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VLA2001,CpG 1018
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: U.K. Government
Deal Size: $1,611.0 million Upfront Cash: Undisclosed
Deal Type: Partnership September 14, 2020
Details:
Valneva’s vaccine candidate, VLA2001, is based on a proven approach and will leverage the company’s existing manufacturing platform being used for its US FDA and EMA approved Japanese Encephalitis (JE) vaccine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoVepiT
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVepiT
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
Data support potential as novel and differentiated COVID-19 vaccine designed against multiple SARS-CoV-2 targets with technology known to induce memory T lymphocytes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VLA2001
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: UK Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 20, 2020
Details:
Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate, to be manufactured at its facilities in Livingston, Scotland.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Covepit
Therapeutic Area: Infections and Infectious Diseases Product Name: Covepit
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Nantes Metropole
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding July 16, 2020
Details:
OSE is working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. This research program aims to develop a prophylactic vaccine focused on memory T cells and based on a multiepitope- peptide approach.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ANT3310,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
Details:
QIDP is granted to Antabio's MEM-ANT3310 for major hospital indications including nosocomial pneumonia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Peptide vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
Vaccine leverages expertise in peptide selection and optimization and proprietary Memopi® technology to explore a T lymphocyte immune response for COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
Study reveal that antiparasitic drug Ivermectin can kill coronavirus in a laboratory setting in under 48 hours. A single treatment is able to effect ?5000-fold reduction in 48h in cell culture.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
